Improving patient outcomes in advanced NSCLC: a focus on molecular diagnostics and resistance SAVE THE DATE

April 13, 2018, 18:40–19:40

Room C, Palexpo, Geneva, Switzerland

OBJECTIVES

Overview the roles of immunotherapy and targeted therapy in treating patients with advanced NSCLC

Highlight the prognostic implications following identification of oncogenic driver aberrations

Discuss the advantages and practicalities of next-generation sequencing (NGS) versus sequential testing (eg by IHC and FISH) to optimize molecular diagnostics

Overview mechanisms of resistance to immunotherapy and targeted therapy and the requirements for routine testing

AGENDA

18:40–18:45	WELCOME AND INTRODUCTIONS Luis Paz-Ares (Chair)
18:45–19:05	AN INTRODUCTION TO TARGETED AND IMMUNE THERAPIES Including opportunity for Q&A Raffaele Califano
19:05–19:25	OPTIMIZING DIAGNOSTICS FOR MOLECULAR ABERRATIONS Including opportunity for Q&A Luis Paz-Ares
19:25–19:40	UNDERSTANDING AND MANAGING RESISTANCE Including opportunity for Q&A Enriqueta Felip
10.10	والمحمو محمور محمور محمور المحمور المحمو

9:40 CLOSE Luis Paz-Ares (Chair)

U NOVARTIS

Novartis Pharma AG CH-4002 Basel Switzerland

02/18

G-LDK-1183404

This program and/or material was developed for use outside of the USA, is intended

for non-US HCPs, and is to be used in accordance with local laws and regulations